Which pharmaceutical companies spent the most in R&D?
KOSPI pharmaceutical companies increased collective R&D expenses by this 3rd quarter year-on-year, but KOSDAQ pharmaceutical companies had a decrease. When it comes to the collective 3rd quarter’s R&D expense/sales rate, the KOSDAQ market had a higher rate than the KOSPI.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.